bioAffinity Technologies, Inc. Accretion Expense
bioAffinity Technologies, Inc. (BIAF) reported Accretion Expense of $2.06 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2024-04-01
- bioAffinity Technologies, Inc. accretion expense for the quarter ending 2022-12-31 was $82.68K.
- bioAffinity Technologies, Inc. accretion expense for the quarter ending 2022-09-30 was $767.69K.
- bioAffinity Technologies, Inc. accretion expense for the quarter ending 2022-06-30 was $227.04K.
- bioAffinity Technologies, Inc. accretion expense for the quarter ending 2022-03-31 was $978.22K.
- bioAffinity Technologies, Inc. accretion expense for fiscal 2022 was $2.06M, a 327.74% increase from fiscal 2021.
- bioAffinity Technologies, Inc. accretion expense for fiscal 2021 was $480.57K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $82.68K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $850.37K derived: sum of 2 quarters · filed 2024-04-01 | $1.08M derived: sum of 3 quarters · filed 2024-04-01 | $2.06M 10-K · filed 2024-04-01 |
| 2022-09-30 | $767.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $994.73K derived: sum of 2 quarters · filed 2023-11-14 | $1.97M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $227.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.21M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $978.22K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $480.57K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |